|1.||Lipton, R B: 4 articles (09/2005 - 03/2001)|
|2.||Winter, P: 4 articles (08/2000 - 02/2000)|
|3.||Becker, Werner J: 3 articles (08/2015 - 09/2013)|
|4.||Ferrari, M D: 3 articles (06/2011 - 10/2001)|
|5.||Massiou, H: 3 articles (10/2005 - 12/2000)|
|6.||Goadsby, P J: 3 articles (09/2005 - 09/2001)|
|7.||Diener, H C: 3 articles (12/2003 - 08/2000)|
|8.||Adelman, J U: 3 articles (10/2001 - 01/2001)|
|9.||O'Quinn, S: 3 articles (03/2001 - 02/2000)|
|10.||Tfelt-Hansen, Peer: 2 articles (06/2011 - 10/2007)|
|1.||Migraine Disorders (Migraine)
07/01/2007 - "In a pilot study, naratriptan was significantly more effective than placebo in preventing menstrually related migraine (MRM) when given as 1 mg twice daily for 5 days beginning 2 days before the predicted onset of MRM for up to 4 menstrual cycles. "
06/01/2007 - "Although naratriptan is not approved for prophylactic use in migraine, naratriptan has been shown to be significantly more effective than placebo for short-term prevention of menstrually related migraine (MRM). "
12/09/2000 - "Those data suggest that the use of naratriptan oral 2.5 mg for the treatment of migraine attacks during a 12 week period may be associated with a significant improvement in migraine patient's quality of life."
02/01/2004 - "Naratriptan is an effective and well-tolerated treatment for acute attacks of migraine. "
10/01/2003 - "Short-term daily administration of naratriptan may be effective in terminating status migrainosus."
05/01/2003 - "There was a statistically significant reduction in the frequency of headache days 2 months (15.3 days versus 24.1 days at baseline, P<.001), 6 months (9.1 days, P<.001), and 1 year (7.3 days, P<.001) after daily treatment with naratriptan was initiated. "
03/01/2000 - "Among headaches that occurred, the majority occurred within 2 h of naratriptan administration, suggesting that naratriptan is more effective in preventing headache if taken early in prodrome. "
12/01/2002 - "The addition of the naratriptan further improved the headaches in seven of the nine patients."
06/01/1999 - "In two Phase III trials of naratriptan compared with placebo, relief at four hours was obtained in 60% and 68% of patients using the 2.5-mg dose, with recurrence of headache in 24 hours in 27% and 28% of patients. "
11/01/2007 - "Naratriptan was prescribed as second-line treatment following failure of an NSAID in 44.2% of patients taking it; 55.3% of them were prescribed a single dose per headache. "
02/15/2001 - "The results of this study suggest central actions of naratriptan and may point to an involvement of the endogenous pain control system in the antinociceptive effects of the 5-HT(1)-receptor-agonist."
10/01/2005 - "A higher percentage of subjects in the naratriptan group (58%) reported complete pain relief 4 h after medication than in the placebo group (30%) (P<0.001). "
10/01/2005 - "To predict the probability of pain relief following oral (tablet) administration of naratriptan, a simple dose response, instead of the PK/PD model, would have yielded very similar predictions. "
01/01/2005 - "Probable sites of therapeutic action of naratriptan include any or all of: the cranial vasculature; the peripheral terminations of trigeminovascular sensory nerves; the first-order synapses of the trigeminovascular sensory system; the descending pain control system; and the nuclei of the thalamus. "
08/01/2000 - "The main reasons for preference for naratriptan therapy were "relieves pain effectively" (86%) and "restores ability to function/perform task" (81%). "
|4.||Sturge-Weber Syndrome (Sturge-Kalischer-Weber Syndrome)
|8.||Caffeine (No Doz)
|10.||Serotonin (5 Hydroxytryptamine)